Advertisement

Topics

Acorda Provides Update on Tozadenant Development Program

07:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Identified cases of agranulocytosis, possibly drug-related, in some cases associated with sepsis and death Increased blood cell count monitoring to weekly in ongoing Phase 3 program ...

Other Sources for this Article

Acorda Therapeutics, Inc.
Investors/Analysts:
Felicia Vonella, 914-326-5146
Investor Relations
fvonella@acorda.com
or
Media:
Tierney Saccavino, 914-326-5104
Corporate Communications
tsaccavino@acorda.com

NEXT ARTICLE

More From BioPortfolio on "Acorda Provides Update on Tozadenant Development Program"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...